Related Experiment Videos
[The antigenic structure of the eastern equine encephalomyelitis virus studied by using monoclonal antibodies]
Abstract:
Thirty-three monoclonal antibodies (Mabs) interacting with the structural proteins of Eastern equine encephalomyelitis (EEE) virus were prepared. The mutual arrangement of the antigenic sites on the E1 and E2 glycoproteins was studied by competitive radioimmunoassay. At least four nonoverlapping sites were found on the E1. The E2 glycoprotein contained at least seven partially overlapping antigenic sites. Mabs to the sites E2-2 and E2-3 neutralized viral infectivity and blocked hemagglutination. Mabs to the site E2-1 blocked hemagglutination. Mabs to sites E2-2, 3, and 7 protected mice against lethal infection although the protective Mabs to sites E2-2b and E2-7 did not neutralize the virus. The antibodies to the other three sites of E2 and to all sites of E1 did not have any biological activity. The experimental results indicate the dominant role of E2 in antiviral immunity, over 98% of the observed protective effect being associated with the E2-2 site.
Insights
This study identified key antigenic sites on Eastern equine encephalitis (EEE) virus proteins. The E2 glycoprotein
Area of Science:
- Virology
- Immunology
- Structural Biology
Context:
- Eastern equine encephalitis (EEE) virus poses a significant public health threat.
- Understanding EEE virus structural proteins is crucial for vaccine and therapeutic development.
- Monoclonal antibodies (mAbs) are valuable tools for probing viral antigenic structures.
Purpose:
- To characterize the antigenic sites on EEE virus E1 and E2 glycoproteins.
- To investigate the biological activities of mAbs targeting these sites.
- To determine the role of specific antigenic sites in viral immunity.
Summary:
- Thirty-three monoclonal antibodies (mAbs) were generated against EEE virus structural proteins E1 and E2.
- Competitive radioimmunoassay revealed at least four sites on E1 and seven overlapping sites on E2.
- mAbs targeting E2 sites, particularly E2-2, demonstrated significant neutralization, hemagglutination inhibition, and protection against lethal infection in mice.
- Antibodies to E1 and other E2 sites showed limited or no biological activity.
- The E2 glycoprotein, especially the E2-2 site, plays a dominant role in antiviral immunity.
Impact:
- Identifies critical antigenic targets on EEE virus for potential therapeutic intervention.
- Highlights the E2 glycoprotein as a primary focus for vaccine design against EEE.
- Provides a detailed antigenic map of EEE virus, aiding future research and development.